Novelix Pharmaceuticals Ltd — Others, 26-08-2025: Others

Novelix Pharmaceuticals has released its Annual Report for FY2024-25 and announced its 31st Annual General Meeting. The company reported a significant revenue increase to 30.72 Cr (from 4.22 Cr) and a Profit After Tax of 0.85 Cr (from 0.10 Cr), reflecting its strategic shift into Life Science Research and Pharmaceutical bulk and Intermediates. The AGM agenda includes adopting financials, re-appointing a director, appointing new secretarial auditors, and seeking shareholder approval for increasing borrowing limits, asset charges, and investments/loans/guarantees up to 500 Cr each. New independent and non-executive directors are also up for appointment.